Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

A prospective study of infliximab withdrawal after 12 months of treatment in patients with Crohn's disease: how will NICE guidance affect patient care?

(2013) L. Blackmore et al.   CLINICAL MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Guidelines for the management of inflammatory bowel disease in adults

(2011) C. Mowat et al.   GUT

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

(2011) Mamoru Watanabe et al.   Journal of Crohns & Colitis

Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data

(2009) K. BODGER et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS